Can Coherus Oncology (CHRS) Stock Reach $7.25?

Coherus Oncology, Inc. (CHRS), a commercial-stage immuno-oncology company formerly known as Coherus BioSciences, has seen its shares collapse to roughly $0.64, near a 52-week low, even as several Wall Street analysts maintain price targets many multiples above the current quote. The resulting question — whether CHRS can reach a $7.25 analyst-derived target — involves one of the widest gaps between market pricing and sell-side expectations in the small-cap biotech universe.

Key Takeaways

• The central target of $7.25 is the arithmetic mean of four current, attributable analyst price targets — H.C. Wainwright ($7), Maxim Group ($4), Guggenheim ($8) and Oppenheimer ($10) — giving a wide range of $4 to $10.
• At a latest verified price near $0.64, reaching $7.25 would require a rise of roughly 1,030%, an extraordinarily large move by any standard.
• Analysts base their targets mainly on the clinical pipeline (tagmokitug and casdozokitug) and Loqtorzi commercialization, using probability-adjusted valuation models, not near-term fundamentals.
• The strongest support comes from Loqtorzi (toripalimab), an approved PD-1 therapy for nasopharyngeal carcinoma, and an encouraging early esophageal-cancer signal for tagmokitug.
• The biggest risks are a disclosed going-concern warning, a cash runway now below 12 months, slowing Loqtorzi growth, and the threat of further dilution or a reverse split.
• Readers can track Major News and Today's Price Move, review the Forecast, and follow Earnings on dedicated pages.
• Explore Trending AI Robots to see AI-driven strategies monitoring stocks like CHRS.

Analyst Price Targets and Consensus View

The $7.25 central target reflects four recent, individually attributed targets: H.C. Wainwright initiated coverage with a Buy and a $7 target in late October 2026, Maxim Group reiterated a Buy with a $4 target, Oppenheimer maintained a $10 target, and Guggenheim — which initiated coverage at $12 in May 2026 — lowered its target to $10 and then to $8 following third-quarter results. The arithmetic mean of these four figures is $7.25, with a low-to-high range of $4 to $10.

The dispersion is unusually wide, underscoring how much the thesis rests on uncertain clinical and financing outcomes. Guggenheim's original work valued the company on a discounted-cash-flow basis driven by tagmokitug's potential in solid tumors, while the lower targets reflect the deteriorating balance sheet. Notably, a separate, older UBS Hold carried a $1.10 target, a reminder that not every published view supports the bullish case. This $7.25 figure is a calculated average of verified individual targets, not an official published consensus.

Current Market Position and Path Toward the Target

Shares closed near $0.64 on November 10, 2026, down more than 20% in a single session after third-quarter results. The stock has fallen about 49% over the past year and roughly 55% year to date, with a 52-week range of $0.60 to $2.62. Reaching $7.25 from $0.64 would require an increase of approximately 1,030%, a very large move that would demand not just a re-rating but a fundamental transformation in the company's liquidity position and clinical pipeline value.

The path toward such a level would likely require positive tagmokitug and casdozokitug data, a resolution of the going-concern overhang through a milestone payment, partnership, or financing, and an acceleration in Loqtorzi sales toward the $25–30 million quarterly level management says is needed to cover core costs. As of the latest quarter, Loqtorzi revenue was about $14 million.

What Could Support a Move Toward the Target

• Loqtorzi is the only FDA-approved treatment for recurrent or metastatic nasopharyngeal carcinoma, and grew sales 25% year over year in the third quarter.
• Tagmokitug showed a 33.3% confirmed response rate in second-line esophageal cancer, with median progression-free survival of 5.5 months versus a chemotherapy benchmark near 10%.
• Two potential $37.5 million Udenyca divestiture milestones could bolster cash if resolved favorably.
• A 30% workforce reduction and narrowed pipeline lower the quarterly revenue needed to approach self-sufficiency.

What Could Prevent the Target From Being Reached

• The company disclosed going-concern language, with cash and investments of roughly $83.6 million and a runway of less than 12 months.
• Loqtorzi growth decelerated sharply, rising only about 3% sequentially and missing management's 10–15% quarterly target.
• Full-year 2026 Loqtorzi guidance was cut to $54–57 million from $57–62 million, and the company missed consensus revenue.
• An ATM facility and convertible-debt overhang create meaningful dilution risk, and the sub-$1 share price raises the possibility of a reverse split.

Technical Levels and Market Structure

CHRS trades below both its 50-day moving average (near $1.16) and 200-day moving average (near $1.52), with shares near the $0.60 52-week low. The $1.00 level represents a key psychological threshold, while $0.85–$0.90 marks a near-term resistance zone from the stock's recent trading range. A durable recovery toward any multi-dollar target would first require reclaiming and holding levels far above current price action.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month horizon, though individual firms vary and this horizon can compress when financing risk is acute. Key items to watch include tagmokitug and casdozokitug clinical data readouts, resolution of the Udenyca earn-out dispute, any partnership, refinancing, or equity raise, Loqtorzi prescription trends, and the next quarterly report. No specific timing for reaching the target should be assumed.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap like CHRS, such tools can help traders screen opportunities, monitor existing positions, and identify shifting trends more efficiently than manual review. Traders interested in a systematic, data-driven layer on top of their own research can explore these signals as one input among many.

Final Assessment

Whether CHRS can reach $7.25 ultimately depends less on near-term earnings than on resolving its liquidity crisis and validating its pipeline. The $7.25 figure is the average of four current analyst targets spanning $4 to $10, implying a move of roughly 1,030% from the present price — a gap driven by probability-weighted valuations of tagmokitug and casdozokitug that the market currently discounts heavily. Supportive factors include an approved, growing drug and encouraging early clinical data, while going-concern risk, slowing Loqtorzi growth, and dilution pressure are the principal obstacles. Investors should monitor cash runway, clinical readouts, and financing developments, recognizing that the target is an analyst estimate, not a forecast of what will occur.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations